Home / Technology & Devices

Technology & Devices

GSK Forms Drug Discovery Alliance with University of California CRISPR Researchers

GlaxoSmithKline plc today announced a five-year collaboration with the University of California to establish a state-of-the-art laboratory for CRISPR technologies, the Laboratory for Genomics Research (LGR). The new laboratory will explore how gene mutations cause disease and develop new technologies using CRISPR to rapidly accelerate the discovery of new medicines. …

Read More »

Synlogic and Ginkgo Bioworks Enter Platform Collaboration for Accelerated Development of Novel Synthetic Biotic Medicines

CAMBRIDGE, Mass. & BOSTON–(BUSINESS WIRE)–Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines and Ginkgo Bioworks, the organism company, today announced a platform collaboration to accelerate expansion and development of Synlogic’s pipeline of Synthetic Biotic medicines using Ginkgo’s cell programming platform. The agreement provides …

Read More »

Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI

BOSTON, June 11, 2019 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) announced that the investigational new drug (IND) application submitted by the National Cancer Institute (NCI) has received clearance from the U.S. Food and Drug Administration (FDA) for a clinical trial in solid tumors to evaluate T-cell …

Read More »

Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer diagnosis, as compared to the original Afirma test. Findings …

Read More »

Janssen and nference Enter R&D Data Science Strategic Partnership that will Leverage nference’s AI Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)–nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization. “We are …

Read More »

Study Demonstrates Ability to Predict Early Rejection in Kidney Transplant with FractalDx Portfolio Technology

NEW YORK, June 7, 2019 /PRNewswire/ — Renalytix AI plc (AIM: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that positive study results have been published in the Journal of Clinical Investigation (JCI) Insight1.  These results show FractalDx portfolio technology can accurately predict early acute …

Read More »

QIAGEN and DiaSorin collaborate on novel QuantiFERON-Based Test for Earlier Detection of Lyme Disease

Germantown, Maryland; Hilden, Germany and Saluggia, Italy, June 5, 2019 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant unmet medical need. The …

Read More »

UC Berkeley Extension and Innovative Genomics Institute Launch CRISPR Genome Editing Courses

BERKELEY, Calif.–(BUSINESS WIRE)–UC Berkeley Extension and the Innovative Genomics Institute (IGI) announce the launch of a practical training on CRISPR and genome editing. CRISPR is infiltrating nearly every crevice of biology, leading to new discoveries and surprising applications. The fast pace of this technology captures news headlines daily, leaving the public to wonder …

Read More »

Bayer and Arvinas to Collaborate on Proteolysis-Targeting Chimera Candidates for Humans and Plants

NEW HAVEN, Conn., June 04, 2019 (GLOBE NEWSWIRE) — Bayer and Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins, today announced an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological, …

Read More »

HitGen Enters into DNA-Encoded Library Based Drug Discovery Research Collaboration with Gilead Sciences

CHENGDU, China–(BUSINESS WIRE)–HitGen Inc. today announced that it has entered into a drug discovery research collaboration with Gilead Sciences to identify potential small molecule leads against targets of interest to Gilead. In this collaboration, HitGen will apply its technology platform, based on DNA-encoded library design, synthesis and interrogation, to discover …

Read More »